Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Therapeutic strategies in RET gene rearranged non-small cell lung cancer
Leylah Drusbosky, Estelamari Rodriguez, Richa Dawar, et al.
Journal of Hematology & Oncology (2021) Vol. 14, Iss. 1
Open Access | Times Cited: 73

Showing 1-25 of 73 citing articles:

Selpercatinib in Patients With RET Fusion–Positive Non–Small-Cell Lung Cancer: Updated Safety and Efficacy From the Registrational LIBRETTO-001 Phase I/II Trial
Alexander Drilon, Vivek Subbiah, Oliver Gautschi, et al.
Journal of Clinical Oncology (2022) Vol. 41, Iss. 2, pp. 385-394
Open Access | Times Cited: 141
Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021
Qing Wu, Wei Qian, Xiaoli Sun, et al.
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 134
Oncogenic alterations in advanced NSCLC: a molecular super-highway
Alex Friedlaender, M. Pérol, Giuseppe Luigi Banna, et al.
Biomarker Research (2024) Vol. 12, Iss. 1
Open Access | Times Cited: 36
Nanomedicine Combats Drug Resistance in Lung Cancer
Xiuli Zheng, Xiao-Hai Song, Guonian Zhu, et al.
Advanced Materials (2023) Vol. 36, Iss. 3
Closed Access | Times Cited: 35
Liquid Biopsies in Lung Cancer
Marcel Kemper, Carolin Krekeler, Kerstin Menck, et al.
Cancers (2023) Vol. 15, Iss. 5, pp. 1430-1430
Open Access | Times Cited: 25
Molecular alterations of driver genes in non-small cell lung cancer: from diagnostics to targeted therapy.
Anna Grodzka, Agnieszka Knopik-Skrocka, Katarzyna Kowalska, et al.
PubMed (2023) Vol. 22, pp. 415-432
Closed Access | Times Cited: 18
Evolution of the Targeted Therapy Landscape for Cholangiocarcinoma: Is Cholangiocarcinoma the ‘NSCLC’ of GI Oncology?
Amol Gupta, Razelle Kurzrock, Jacob J. Adashek
Cancers (2023) Vol. 15, Iss. 5, pp. 1578-1578
Open Access | Times Cited: 16
Primary Resistance to RET Inhibition in a RET Fusion-Positive Pancreatic Neuroendocrine Carcinoma
Blake McKinley, Tucker W Coston, Jason S. Starr
The Oncologist (2024) Vol. 30, Iss. 1
Open Access | Times Cited: 6
Resistance of Lenvatinib in Hepatocellular Carcinoma
Qiuran Xu, Dong‐Sheng Huang, Jinhui Guo, et al.
Current Cancer Drug Targets (2022) Vol. 22, Iss. 11, pp. 865-878
Closed Access | Times Cited: 25
Deep learning-based tumor microenvironment segmentation is predictive of tumor mutations and patient survival in non-small-cell lung cancer
Alicja Rączkowska, Iwona Paśnik, Michał Kukiełka, et al.
BMC Cancer (2022) Vol. 22, Iss. 1
Open Access | Times Cited: 22
Treatment of advanced non-small cell lung cancer with driver mutations: current applications and future directions
Jia Zhong, Hua Bai, Zhijie Wang, et al.
Frontiers of Medicine (2023) Vol. 17, Iss. 1, pp. 18-42
Closed Access | Times Cited: 14
The expression and functional role of proline-rich 15 in non-small cell lung cancer
Yong Ji, Han Zhang, Fuxing Gong, et al.
Cell Death and Disease (2025) Vol. 16, Iss. 1
Open Access
Safety, pharmacokinetics and efficacy of HA121-28 in patients with advanced solid tumors and RET fusion-positive non-small-cell lung cancer: a multicenter, open-label, single-arm phase 1/2 trial
Dan‐Yun Ruan, Wenwen Huang, Yongsheng Li, et al.
Signal Transduction and Targeted Therapy (2025) Vol. 10, Iss. 1
Open Access
Optimizing Cardiovascular Treatment in Non-Small Cell Lung Cancer: A Comprehensive Computational Approach for Assessment of Drug-Drug Interactions between Tyrosine Kinase Inhibitors and Cardiovascular Drugs
Prajakta Patil, Mrunal Desai, Gayathri Baburaj, et al.
F1000Research (2025) Vol. 14, pp. 309-309
Open Access
Cerebrospinal fluid circulating tumor DNA depicts profiling of brain metastasis in NSCLC
Jun Wu, Zhiqiang Liu, Tianxiang Huang, et al.
Molecular Oncology (2022) Vol. 17, Iss. 5, pp. 810-824
Open Access | Times Cited: 21
Complications following novel therapies for non‐small cell lung cancer
Marcus Skribek, Konstantinos Rounis, Georgios Tsakonas, et al.
Journal of Internal Medicine (2022) Vol. 291, Iss. 6, pp. 732-754
Open Access | Times Cited: 20
Efficacy and safety of selpercatinib in Chinese patients with advanced RET fusion-positive non-small-cell lung cancer: a phase II clinical trial (LIBRETTO-321)
Shun Lü, Ying Cheng, Dingzhi Huang, et al.
Therapeutic Advances in Medical Oncology (2022) Vol. 14
Open Access | Times Cited: 20
Consensus Recommendations to Optimize Testing for New Targetable Alterations in Non-Small Cell Lung Cancer
Diana N. Ionescu, Tracy Stockley, Shantanu Banerji, et al.
Current Oncology (2022) Vol. 29, Iss. 7, pp. 4981-4997
Open Access | Times Cited: 19
Treatment of Advanced Non-Small Cell Lung Cancer with RET Fusions: Reality and Hopes
Danilo Rocco, Luigi Sapio, Luigi Della Gravara, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 3, pp. 2433-2433
Open Access | Times Cited: 11
A comprehensive overview of the relationship between RET gene and tumor occurrence
Lu Zhao, Na Wang, Dou Zhang, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 11
Pyrazolopyridine-based kinase inhibitors for anti-cancer targeted therapy
Pallabi Halder, Anubhav Rai, Vishal Talukdar, et al.
RSC Medicinal Chemistry (2024) Vol. 15, Iss. 5, pp. 1452-1470
Closed Access | Times Cited: 4
Exploring histopathological and serum biomarkers in lung adenocarcinoma: Clinical applications and translational opportunities (Review)
Miguel Á. Ortega, Fátima Navarro, Leonel Pekarek, et al.
International Journal of Oncology (2022) Vol. 61, Iss. 6
Open Access | Times Cited: 17
Updated Views in Targeted Therapy in the Patient with Non-Small Cell Lung Cancer
Miguel Á. Ortega, Leonel Pekarek, Fátima Navarro, et al.
Journal of Personalized Medicine (2023) Vol. 13, Iss. 2, pp. 167-167
Open Access | Times Cited: 10
Mechanisms of resistance to tyrosine kinase inhibitor‐targeted therapy and overcoming strategies
Xuejin Ou, Ge Gao, Inbar A. Habaz, et al.
MedComm (2024) Vol. 5, Iss. 9
Open Access | Times Cited: 3
Integration of rapid PCR testing as an adjunct to NGS in diagnostic pathology services within the UK: evidence from a case series of non-squamous, non-small cell lung cancer (NSCLC) patients with follow-up
Alison Finall, Gareth Reynold Davies, Trevor Jones, et al.
Journal of Clinical Pathology (2022) Vol. 76, Iss. 6, pp. 391-399
Closed Access | Times Cited: 14
Page 1 - Next Page

Scroll to top